PT141

PT-141 / Bremelanotide research reference

PT-141 is commonly associated with bremelanotide, a melanocortin-receptor agonist. In the United States, a regulated bremelanotide medicine is approved for a specific indication in premenopausal women with acquired, generalized hypoactive sexual desire disorder. That approval is specific to the regulated medicine, formulation and indication and does not apply to this VELAIA listing.

Research areas

• Melanocortin receptor signaling.
• Central pathways related to sexual-response research.
• Pharmacology of melanocortin agonists.

Evidence context

Do not extrapolate an approval for a specific medicine to other formulations, products or uses.

For research purposes only. Not intended for human consumption, self-administration or use as a medicine.